EntreMed Receives Orphan Drug Designation For ENMD-2076 In Leukemia

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

EntreMed, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.